Castle biosciences stock.

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago.Nov 27, 2023 · Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47. Studies have shown that using Castle’s DecisionDx®-Melanoma test to help guide the care of patients with melanoma, the deadliest form of skin cancer, improves health outcomes1-5 Castle’s...Ellen Goldberg CSTL stock SEC Form 4 insiders trading. Ellen has made over 4 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Ellen exercised 440 units of CSTL stock worth $7,911 on 14 July 2023.440 units of CSTL stock worth $7,911 on 14 July 2023.

Castle Biosciences Inc Credit and Debit Option Spread prices and quotes.S hares of Castle Biosciences (NASDAQ: CSTL) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is ...

PURPOSE KRAS is the most mutated proto-oncogene that has been identified in cancer, and treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRASG12C mutation has attracted special interest because it is now considered potentially druggable with recently developed covalent small-molecule KRASG12C inhibitors. …

Mr. Maetzold CSTL stock SEC Form 4 insiders trading. Derek has made over 105 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,500 units of CSTL stock worth $30,075 on 1 September 2023.. The largest trade he's ever made was exercising 65,627 units of Castle …Nov 24, 2023 · Castle Biosciences Inc CSTL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating... NASDAQ: CSTL + 19.38 -0.68 ( -3.39% ) Minimum 20 minutes delayed November 21, 2023 4:00 PM Overview Castle Biosciences is improving health through …The all-time high Castle Biosciences stock closing price was 97.33 on February 09, 2021. The Castle Biosciences 52-week high stock price is 29.59, which is 64.4% above the current share price. The Castle Biosciences 52-week low stock price is 9.26, which is 48.6% below the current share price. The average Castle Biosciences stock price for the ...

As soon as the Novitas decision reversal decision was announced, Castle stock began to climb, jumping from ~$13 per share, to nearly $20 per share, a >50% gain that leaves Castle more or less back ...

May 30, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 8.79% so far this month. During the month of May, Castle Biosciences Inc’s stock price has reached a high of $26.70 and a low of $20.56. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $15.58. Year to date ...

31 Eki 2023 ... About Castle Biosciences Inc (CSTL). Before we jump into Castle Biosciences Inc's stock price, history, target price and what caused it to ...6 hours ago · Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma. The estimated Net Worth of David S Kabakoff is at least $76.2 Million dollars as of 17 June 2021. David Kabakoff owns over 30,000 units of Castle Biosciences stock worth over $11,536,949 and over the last 4 years he sold CSTL stock worth over $64,362,650. In addition, he makes $288,339 as Independent Director at Castle …The primary residents of European castles during the Middle Ages were the lord and lady of the realm. These might be royalty or simply the liege lords of the district where the castle was built.Revenue growth over the past 12 months for CASTLE BIOSCIENCES INC comes in at 55.17%, a number that bests 91.18% of the US stocks we're tracking. Stocks with similar financial metrics, market capitalization, and price volatility to CASTLE BIOSCIENCES INC are SILK, ONTF, IGC, FLGT, and BMRA. Visit CSTL's SEC page to see the company's …Castle Biosciences to Participate in Upcoming Investor Conferences. FRIENDSWOOD, Texas-- (BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle …

Castle Biosciences had a GAAP loss of 70 cents a share, approximately 20 cents a share above expectations. Revenues rose 44% on a year-to-year basis to $50.1 million, almost $6 million over the ...Europe PMC is an archive of life sciences journal literature.Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago.The estimated Net Worth of Mara G. Aspinall is at least $2.81 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $2,014,618 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Nov 14, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago. Nov 8, 2023 · At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

The estimated Net Worth of Mara G. Aspinall is at least $2.42 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,626,983 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.

Future criteria checks 1/6. Castle Biosciences is forecast to grow earnings and revenue by 32.8% and 14.8% per annum respectively. EPS is expected to grow by 32.1% per annum. Return on equity is forecast to be -26.8% in 3 years.Castle Biosciences is the only provider of 31-GEP testing, and all testing is performed in a College of American Pathologists/Clinical Laboratory Improvement Amendments–certified laboratory. We evaluated the ability of the 31-GEP to stratify risk in MSS and overall survival (OS) to confirm the prognostic ability of the 31-GEP at the …The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...How much is Castle Biosciences stock worth today? ( NASDAQ: CSTL) Castle Biosciences currently has 26,910,548 outstanding shares. With Castle Biosciences stock trading at $18.06 per share, the total value of Castle Biosciences stock (market capitalization) is $486.00M. Castle Biosciences stock was originally listed at a price of $21.40 in Jul ...Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ...The estimated Net Worth of Kristen M Oelschlager is at least $2.3 Million dollars as of 28 December 2022. Ms. Oelschlager owns over 7,178 units of Castle Biosciences stock worth over $1,593,448 and over the last 2 years she sold CSTL stock worth over $710,200. In addition, she makes $0 as Senior Vice President - Clinical …Of the 172 institutional investors that purchased Castle Biosciences stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Granahan Investment Management LLC ($1.82M), Principal Financial Group Inc. ($1.13M), Millennium Management LLC ($1.03M), Wasatch Advisors Inc. …

The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set a price target for …

Jun 2, 2023 · Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ...

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences ( CSTL – Research Report ), with a price target of $43.00. The company’s shares closed ...Castle Biosciences Company Info. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. According to 7 analyst offering 12-month price targets in the last 3 months, Castle Biosciences has an average price target of $35.14 with a high of $41.00 and a low of $25.00.As soon as the Novitas decision reversal decision was announced, Castle stock began to climb, jumping from ~$13 per share, to nearly $20 per share, a >50% gain that leaves Castle more or less back ...The estimated Net Worth of Joseph C. Iii Cook is at least $56 Million dollars as of 18 March 2021. Mr. Cook owns over 12,229 units of Castle Biosciences stock worth over $2,473,211 and over the last 4 years he sold CSTL stock worth over $53,227,575. In addition, he makes $286,714 as Independent Director at Castle Biosciences.Mr. Spiess CSTL stock SEC Form 4 insiders trading. Bernhard has made over 9 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of CSTL stock worth $29,070 on 10 December 2021.. The largest trade he's ever made was selling 40,000 units of Castle …Nov 3, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new discovery data from an ongoing study exploring the potential for developing a complementary, minimally invasive test to evaluate small, suspicious lesions of uncertain malignant potential in patients’ eyes. Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Leadership: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Patents with Castle Biosciences. No other potential conflicts of interest were reported. OPTIONS & TOOLS. Export Citation: Track Citation: Add To Favorites: Rights & Permissions; COMPANION …

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...The estimated Net Worth of Bernhard E. Spiess is at least $7.14 Million dollars as of 10 December 2021. Mr. Spiess owns over 1,500 units of Castle Biosciences stock worth over $346,275 and over the last 4 years he sold CSTL stock worth over $6,796,778. In addition, he makes $0 as Chief Business Officer at Castle Biosciences.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive …The estimated Net Worth of Kristen M Oelschlager is at least $2.3 Million dollars as of 28 December 2022. Ms. Oelschlager owns over 7,178 units of Castle Biosciences stock worth over $1,593,448 and over the last 2 years she sold CSTL stock worth over $710,200. In addition, she makes $0 as Senior Vice President - Clinical …Instagram:https://instagram. stock broker for international investorssprott etfdg stovkstock versus According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ... Ellen Goldberg CSTL stock SEC Form 4 insiders trading. Ellen has made over 4 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Ellen exercised 440 units of CSTL stock worth $7,911 on 14 July 2023.440 units of CSTL stock worth $7,911 on 14 July 2023. nue stock forecastklaviyo nyse Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive … coinbase stoc Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 22.91% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...Castle Biosciences is registered under the ticker NASDAQ:CSTL . Their stock opened with $16.00 in its Jul 24, 2019 IPO. Castle Biosciences is funded by 11 investors. Spindletop Capital Management and BrightEdge Fund are the most recent investors. Castle Biosciences has acquired 3 organizations. Their most recent acquisition was AltheaDx …